Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan;9(1):101-7.

Seletracetam, a Small Molecule SV2A Modulator for the Treatment of Epilepsy

  • PMID: 18183537

Seletracetam, a Small Molecule SV2A Modulator for the Treatment of Epilepsy

John R Pollard. Curr Opin Investig Drugs. .


UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.

Similar articles

  • Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
    Matagne A, Margineanu DG, Potschka H, Löscher W, Michel P, Kenda B, Klitgaard H. Matagne A, et al. Eur J Pharmacol. 2009 Jul 1;614(1-3):30-7. doi: 10.1016/j.ejphar.2009.04.024. Epub 2009 Apr 19. Eur J Pharmacol. 2009. PMID: 19383493
  • Brivaracetam UCB.
    Malawska B, Kulig K. Malawska B, et al. Curr Opin Investig Drugs. 2005 Jul;6(7):740-6. Curr Opin Investig Drugs. 2005. PMID: 16044671 Review.
  • Seletracetam (UCB 44212).
    Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N. Bennett B, et al. Neurotherapeutics. 2007 Jan;4(1):117-22. doi: 10.1016/j.nurt.2006.11.014. Neurotherapeutics. 2007. PMID: 17199025 Review.
  • Brivaracetam: First Global Approval.
    Markham A. Markham A. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. Drugs. 2016. PMID: 26899665 Review.
  • Brivaracetam for the treatment of epilepsy.
    Klein P, Tyrlikova I, Brazdil M, Rektor I. Klein P, et al. Expert Opin Pharmacother. 2016;17(2):283-95. doi: 10.1517/14656566.2016.1135129. Epub 2016 Jan 13. Expert Opin Pharmacother. 2016. PMID: 26760311 Review.
See all similar articles

Cited by 4 articles

MeSH terms